Sulfinpyrazone is a platelet inhibitory and uricosuric agent used to inhibit thrombotic and embolic processes and to manage the chronic phases of gout . A uricosuric drug that is used to reduce the serum urate levels in gout therapy.
- Mechanism
- Curator reviewed
Sulfinpyrazone is an oral uricosuric agent (pyrazolone derivative) used to treat chronic or intermittent gouty arthritis. Sulfinpyrazone competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby facilitating urinary excretion of uric acid and decreasing plasma urate concentrations. This is likely done through inhibition of the urate anion transporter (hURAT1) as well as the human organic anion transporter 4 (hOAT4). Sulfinpyrazone is not intended for the treatment of acute attacks because it lacks therapeutically useful analgesic and anti-inflammatory effects. Sulfinpyrazone and its sulfide metabolite possess COX inhibitory effects. Sulfinpyrazone has also been shown to be a UDP-glucuronsyltransferase inhibitor and a very potent CYP2C9 inhibitor. Sulfinpyrazone is also known to be a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor as well as an inhibitor of several multridrug resistance proteins (MRPs).
- Primary indication
- For the treatment of gout and gouty arthritis.Curator reviewed · 2 structured indications
- Formula / weight
- C23H20N2O3S · 404.482 g/mol (avg)
- First approval
- Canada, 1997 · United States, 1959
- Also known as
- Sulfoxyphenylpyrazolidine · Sulphinpyrazone
- Code names
- NSC-75925 · USAF GE-13
Resolves to
MBGGBVCUIVRRBF-UHFFFAOYSA-NSMILESO=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Sulfinpyrazone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account